Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | CTSA | P10619 | 3/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.32 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160037 | 0.85 | JAK1 (0.38) | JAK1TYK2CDK2JAK2JAK3 | |
| SCHEMBL9920326 | 0.83 | JAK2 (0.33) | JAK1TYK2JAK2JAK3MAP4K4 | |
| SCHEMBL9920450 | 0.69 | JAK2 (0.33) | JAK1TYK2JAK2JAK3MAP4K4 | |
| SCHEMBL1160348 | 0.67 | JAK2 (0.56) | JAK1TYK2JAK2JAK3 | |
| SCHEMBL9923338 | 0.64 | CDK2 (0.49) | JAK1TYK2CDK2MAP4K4MAP2K1 | |
| SCHEMBL1160527 | 0.64 | MAP2K1 (0.53) | JAK1TYK2CDK2MAP2K1EPHB3 | |
| SCHEMBL14017228 | 0.64 | CDK2 (0.45) | JAK1TYK2CDK2JAK2JAK3 | |
| SCHEMBL1160511 | 0.62 | JAK1 (0.35) | JAK1TYK2CDK2JAK2JAK3 | |
| SCHEMBL1160281 | 0.60 | JAK1 (0.64) | JAK1TYK2CDK2JAK2JAK3 | |
| SCHEMBL1160492 | 0.60 | JAK1 (0.63) | JAK1TYK2CDK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885TYK2 10/4885CDK2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.